CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 81 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $125,660,422 | +3356.0% | 4,225,300 | +1766.3% | 0.37% | +3236.4% |
Q1 2023 | $3,635,984 | -85.4% | 226,400 | -83.4% | 0.01% | -87.1% |
Q4 2022 | $24,906,300 | -3.2% | 1,361,000 | +3.9% | 0.08% | -17.5% |
Q3 2022 | $25,732,000 | +3.5% | 1,310,200 | -1.7% | 0.10% | -1.9% |
Q2 2022 | $24,857,000 | -6.1% | 1,332,800 | +10.5% | 0.10% | 0.0% |
Q1 2022 | $26,479,000 | -15.6% | 1,206,338 | +9.2% | 0.10% | -16.0% |
Q4 2021 | $31,378,000 | +231.4% | 1,104,476 | +145.5% | 0.12% | +197.6% |
Q3 2021 | $9,468,000 | -29.1% | 449,800 | -36.5% | 0.04% | -30.0% |
Q2 2021 | $13,348,000 | -31.5% | 708,133 | -44.5% | 0.06% | -34.1% |
Q1 2021 | $19,482,000 | +12.7% | 1,275,000 | +4.1% | 0.09% | +8.3% |
Q4 2020 | $17,285,000 | +115.4% | 1,225,003 | +139.3% | 0.08% | +104.9% |
Q3 2020 | $8,023,000 | +16.0% | 511,988 | +29.7% | 0.04% | -8.9% |
Q2 2020 | $6,917,000 | +713.8% | 394,832 | +1065.9% | 0.04% | +1025.0% |
Q4 2019 | $850,000 | -57.2% | 33,865 | -74.3% | 0.00% | -66.7% |
Q3 2019 | $1,985,000 | – | 132,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 623,819 | $11,336,501 | 9.41% |
Finepoint Capital LP | 822,745 | $15,056 | 4.87% |
Bain Capital Life Sciences Investors, LLC | 2,305,558 | $42,192 | 4.72% |
Opaleye Management Inc. | 732,000 | $13,395,600 | 4.66% |
5AM Venture Management, LLC | 862,286 | $15,779,834 | 4.24% |
SPHERA FUNDS MANAGEMENT LTD. | 671,644 | $12,291,085 | 2.64% |
First Light Asset Management, LLC | 1,329,313 | $24,326,428 | 2.26% |
BRAIDWELL LP | 3,469,674 | $63,495,034 | 2.13% |
BVF INC/IL | 2,736,613 | $50,080,018 | 2.11% |
Perceptive Advisors | 4,039,276 | $73,918,751 | 2.08% |